top of page
Melius Pharma Chronic cough in Idiopathic Pulmonary Fibrosis (IPF).jpeg

Board of Directors

Melius Pharma Board is composed of Directors that span a wide area of competencies. Our Board guides the company with both local and international experience and network.

Contact us

The Board

Peter Heinrich

Karl Tobieson

Christer Fåhraeus

Christine Lemke

Niels Skjærbæk

Peter Heinrich
Chairman of the Board

Peter Heinrich_edited.jpg
  • Peter has more than 20 years of experience in the pharma and biotech industry.

  • He has been directly involved in start-ups, as well as publicly-held entities, improving shareholder value, and M&A agreements.

  • He is the co-founder of Sinfonie Life Science Management GmbH, MediGene AG, Immunocore, and Adaptimmune.

  • He was CEO of MagForce AG, a MedTech company, and serves on the Board of the Federation of German Industries (BDI), as well as in board leadership positions for BIO Deutschland and EuropaBio.

  • Peter holds a PhD in biology and chemistry from Ludwig-Maximilians University in München.

Peter

Karl Tobieson

Karl Tobieson_edited.jpg
  • Karl Tobieson is the CEO of LINC AB.

  • Karl previously was CEO of MedCap AB (publ) 2008-2020, where he is now Chairman of the board. Prior to that, he ran a corporate finance company together with a partner and before that he was Investment Manager at Centrecourt and Cell Innovation.

  • Karl has a master’s degree in mechanical engineering with a focus on industrial economics, from the Royal Institute of Technology in Stockholm.

  • Other current assignments include Chairman of the Board of Unimedic AB, Unimedic Pharma AB, Unimedic Pharma Holding AB, Cardiolex Medical AB and Abilia Sverige Holding AB, Board member of Cardiolex AB and Dunmedic AB, Deputy Board member of Abilia AB and Cross Pharma AB.

Karl

Christer Fåhraeus

Christer Fåhraeus.jpg
  • Christer Fåhraeus is CEO of Fårö Capital AB and investment responsible for Fåhraeus Start-up and Growth Fund AB.

  • For the last 18 years Christer has founded and developed companies in pharmaceuticals, biotech, optics, image and signal processing and semi-conductors.

  • He was an MD/PhD student from 1989 until 1994 when he founded his first company, CellaVision AB.

  • He received his MS degree in Bioengineering from University of California San Diego. He holds a Bachelor with double majors in math and physics from Lund University, Sweden.

  • In 2002 he received an honorary PhD in Engineering from Lund University as the youngest person to achieve this honor in its 350 year history.

  • Christer is the inventor of more than 50 patent families and has received numerous awards for scholastic and entrepreneurial achievements.

  • Christer has served as President and CEO for start-ups and high-tech companies for more than 18 years and he has more than 90 Board years of experience from listed and private companies, a third of these as Chairman.

Christer

Christine Lemke

Christine Lemke_edited.jpg
  • Christine has more than 20 years of experience in the pharma and biotech industry.

  • She has been involved in corporate and business development, R&D, operations as well as financial management in the pharmaceutical, medical device and biotech industry

  • Christine is serving as SVP, Portfolio & Growth Strategy at Absci

  • She is chairperson of the Board at Acousia Therapeutics GmbH and member of the Business Development Board at Sunstone Life Science Ventures A/S

  • Christine is Doctor in veterinary medicines from School of Veterinary Medicine in Hannover and has an Executive MBA from University of Colorado, Denver

Christine

Niels Skjærbæk

Niels Skjærbæk_edited.jpg
  • Niels Skjærbæk is educated as a pharmacist and subsequent obtained a PhD in Medicinal Chemistry. Niels has 25 years of working experience from both biotech and pharma industry and he has a broad understanding of drug development processes, ranging from early idea phase until commercialization.

  • Niels started his career at ACADIA Pharmaceuticals as department head and responsible for medicinal chemistry activities, with focus on delivering novel, potent and selective small molecules targeting pharmacological receptors within CNS. Subsequently Niels has had several business development positions within both private and public functions

  • Niels is currently partner at Marigold Innovation.

Niels
bottom of page